APIIC and its partners have been awarded $14 million in federal funding to lead the development and domestic production of three critical APIs used in the treatment of asthma, diabetes and anxiety disorders.

APIIC and its partners have been awarded $14 million in federal funding to lead the development and domestic production of three critical APIs used in the treatment of asthma, diabetes and anxiety disorders.
APIIC and its partners have been awarded $14 million in federal funding to lead the development and domestic production of three critical APIs used in the treatment of asthma, diabetes and anxiety disorders.
APIIC and its partners have been awarded $14 million in federal funding to lead the development and domestic production of three critical APIs used in the treatment of asthma, diabetes and anxiety disorders.
The funding will go toward enhancing Succeed programming, strengthening vocational and academic opportunities and improving transition services.